Bluebird Bio Warns of Potential Bankruptcy Amid Delayed Buyout Bluebird Bio, a company specializing in gene therapy, has recently come under significant financial pressure as it navigates a tumultuous buyout process with Carlyle Group and SK Capital. A mere 25.6% of Bluebird’s outstanding shares were tendered by the deadline for the acquisition, far below the …
Continue reading “Bluebird Bio Faces Bankruptcy Risk as Shareholder Support for Buyout Lags”
